000272870 001__ 272870
000272870 005__ 20250120102326.0
000272870 020__ $$a978-1-0716-4082-1 (print)
000272870 020__ $$a978-1-0716-4083-8 (electronic)
000272870 0247_ $$2doi$$a10.1007/978-1-0716-4083-8_17
000272870 0247_ $$2ISSN$$a0893-2336
000272870 0247_ $$2ISSN$$a1940-6045
000272870 037__ $$aDZNE-2024-01287
000272870 082__ $$a610
000272870 1001_ $$aGroppa, Sergiu$$b0$$eEditor
000272870 245__ $$aTranslational View on Therapeutic Strategies and Upcoming Issues: Stem Cell and Brain Organoid Approaches for Parkinson’s Disease Therapy
000272870 260__ $$aNew York, NY$$bSpringer US$$c2025
000272870 29510 $$aTranslational Methods for Parkinson’s Disease and Atypical Parkinsonism Research / Groppa, Sergiu (Editor) ; New York, NY : Springer US, 2025, Chapter 17 ; ISSN: 0893-2336=1940-6045 ; ISBN: 978-1-0716-4082-1=978-1-0716-4083-8 ; doi:10.1007/978-1-0716-4083-8
000272870 300__ $$a241 - 275
000272870 3367_ $$2ORCID$$aBOOK_CHAPTER
000272870 3367_ $$07$$2EndNote$$aBook Section
000272870 3367_ $$2DRIVER$$abookPart
000272870 3367_ $$2BibTeX$$aINBOOK
000272870 3367_ $$2DataCite$$aOutput Types/Book chapter
000272870 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1730721095_28268
000272870 4900_ $$aNeuromethods$$v213
000272870 520__ $$aThere are currently no disease-modifying therapies for Parkinson’s disease (PD), and the available therapies only relieve the symptoms and not disease progression. Cell replacement therapy to restore the degenerating neurons is a promising approach to treating advanced stages of PD. The idea behind cell therapy dates back to the 1970s, when the first transplantation of fetal ventral mesencephalic tissue was performed on neurotoxic animal models of PD and showed promising motor recovery and graft survival. Based on this early proof of concept, several other cell types from different sources—e.g., embryonic stem cells or induced pluripotent stem cells—were tested and used in several preclinical studies, leading to transplantation into a small number of human subjects. After proving the safety of the method and the overall positive clinical outcome, several clinical trials were organized in Europe, in the United States, and in the rest of the world. In this chapter, we describe the story of modern stem cell-based clinical trials for the treatment of PD and highlight the successes and limitations of these approaches as well as the key discoveries associated with it. Part of the chapter is also dedicated to the use of brain organoids as a new promising interface between in vitro and in vivo models, which could lead to the development of novel disease-relevant insights and new promising therapeutic avenues in the near future.
000272870 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272870 588__ $$aDataset connected to CrossRef Book Series, Journals: pub.dzne.de
000272870 7001_ $$aSchneider, Susanne A.$$b1$$eEditor
000272870 7001_ $$0P:(DE-2719)9002293$$aGubinelli, Francesco$$b2$$udzne
000272870 7001_ $$aSalazar, Jose M.$$b3
000272870 7001_ $$aKaspar, Janina$$b4
000272870 7001_ $$aOrtiz, Irene Santisteban$$b5
000272870 7001_ $$aSchafer, Simon T.$$b6
000272870 7001_ $$0P:(DE-2719)9000040$$aBurbulla, Lena F.$$b7$$eLast author$$udzne
000272870 773__ $$a10.1007/978-1-0716-4083-8_17
000272870 8564_ $$uhttps://pub.dzne.de/record/272870/files/DZNE-2024-01287.pdf
000272870 8564_ $$uhttps://pub.dzne.de/record/272870/files/DZNE-2024-01287.pdf?subformat=pdfa$$xpdfa
000272870 909CO $$ooai:pub.dzne.de:272870$$pVDB
000272870 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002293$$aExternal Institute$$b2$$kExtern
000272870 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000272870 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272870 9141_ $$y2024
000272870 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000272870 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000272870 9201_ $$0I:(DE-2719)5000074$$kAG Burbulla$$lTranslational Disease Modeling$$x0
000272870 980__ $$acontb
000272870 980__ $$aVDB
000272870 980__ $$aI:(DE-2719)5000074
000272870 980__ $$aUNRESTRICTED